Eris Lifesciences profit and loss

Latest FY26

Revenue: ₹3,129cr+8.1% on FY25
EBITDA: ₹1,120cr+10.1% on FY25
Net profit: ₹648cr+72.8% on FY25
EPS: ₹45.33+75.4% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	3,330	3,129	2,894	2,009	1,685	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	7.8	7.8	18.4	23.8	11.2
	3,337	3,137	2,912	2,033	1,696
	376	327	276	178	142
	539	491	473	202	206
	−41.6	−21.6	−35.5	0.7	3.8
	578	557	505	404	346
	188	193	231	84.8	26.2
	285	280	315	183	117
	718	657	657	550	450
	2,642	2,481	2,423	1,602	1,292
	1,161	1,120	1,017	675	537
	875	841	702	492	420
Profit
	696	656	489	431	405
	−53.1	−17.2	0.0	0.0	0.0
	643	638	489	431	405
	−3.8	157	112	82.2	74.7
	−74.5	−166	2.4	−48.0	−44.2
	−78.2	−9.0	114	34.2	30.5
	−2.4	0.1	0.1	0.0	0.0
	718	648	375	397	374
	721	647	375	397	374
	−1.4	−1.4	−3.3	−3.1	0.1
	717	646	371	394	374
	708	620	352	392	382
	10.9	28.0	22.8	5.1	−8.0
Per share
	₹51.46	₹45.33	₹25.85	₹28.82	₹28.10
	₹51.39	₹45.26	₹25.81	₹28.79	₹28.07
Revenue detail — as filed
	—	−0.1	0.0	0.0	0.0
Other comprehensive income — detail
	−1.4	−1.4	−3.3	—	—
	2.1	0.1	−3.6	−4.6	−0.0
	0.4	−0.2	−0.3	—	—
	—	—	—	−1.6	−0.1
	−4.2	−2.4	—	—	—
	−1.0	−0.6	—	—	—
	706	618	349	389	382
	10.9	28.0	22.7	5.1	−7.9
Per share — as-filed variants
	₹51.46	₹45.33	₹25.85	₹28.82	₹28.10
	₹51.39	₹45.26	₹25.81	₹28.79	₹28.07
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	2,456	2,334	2,180	1,629	1,333
	73.8%	74.6%	75.3%	81.1%	79.1%
Adjusted (ex-exceptional items) — derived
	696	656	489	431	405
	−53.1	−17.2	0.0	0.0	0.0
	772	665	375	397	374
	₹55.27	₹46.54	₹25.85	₹28.82	₹28.10

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ERIS₹1,163.60

Eris Lifesciences Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersMANKIND AJANTPHARM TORNTPHARM EMCURE GRANULES CONCORDBIO INDGN CAPLIPOINTMcap ₹16,116 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	1,685.1	2,009.1	2,893.6	3,129.4	3,329.6
Other Income	11.2	23.8	18.4	7.8	7.8
Total Income	1,696.3	2,033.0	2,912.0	3,137.2	3,337.5
Expenses
+ Cost of Materials Consumed	142.2	177.8	276.3	326.7	376.1
+ Purchases of Stock-in-Trade	206.3	201.5	473.1	490.6	539.1
+ Changes in Inventories	3.8	0.7	-35.5	-21.6	-41.6
+ Employee Benefit Expense	346.2	403.8	505.1	556.8	577.5
+ Finance Costs	26.2	84.8	231.3	192.7	187.5
+ Depreciation & Amortisation	117.1	182.6	315.5	279.5	285.4
+ Other Expenses	449.9	550.5	657.4	656.9	717.8
Total Expenses	1,291.7	1,601.7	2,423.2	2,481.5	2,641.8
EBITDA	536.7	674.8	1,017.2	1,120.1	1,160.8
EBIT	419.7	492.2	701.7	840.6	875.4
Profit
PBT before Exceptional Items	404.6	431.2	488.8	655.7	695.7
+ Exceptional Items	0.0	0.0	0.0	-17.2	-53.1
Pretax Income	404.6	431.2	488.8	638.5	642.5
+ Current Tax	74.7	82.2	111.8	157.4	-3.8
+ Deferred Tax	-44.2	-48.0	2.4	-166.4	-74.5
Tax Expense	30.5	34.2	114.2	-9.0	-78.2
+ Share of Associates & JVs	0.0	0.0	0.1	0.1	-2.4
Net Income	374.2	397.1	374.7	647.5	718.4
+ Net Income — Continuing Ops	374.2	397.1	374.6	647.4	720.8
+ Other Comprehensive Income	0.1	-3.1	-3.3	-1.4	-1.4
Total Comprehensive Income	374.2	394.0	371.4	646.1	717.0
Net Income to Common	382.2	392.0	351.8	619.5	707.6
Minority Interest	-8.0	5.1	22.8	28.0	10.9
Per Share
Basic EPS	28.10	28.82	25.85	45.33	51.46
Diluted EPS	28.07	28.79	25.81	45.26	51.39
Revenue Detail — as filed
+ Share of P&L — Partnership Firms / LLPs	0.0	0.0	0.0	-0.1	—
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-3.3	-1.4	-1.4
+ Items NOT to be Reclassified to P&L	-0.0	-4.6	-3.6	0.1	2.1
+ Tax on Items NOT to be Reclassified	—	—	-0.3	-0.2	0.4
+ Tax on Items NOT to be Reclassified — alt tag	-0.1	-1.6	—	—	—
+ Items to be Reclassified to P&L	—	—	—	-2.4	-4.2
+ Tax on Items to be Reclassified	—	—	—	-0.6	-1.0
Comprehensive Income — Owners of Parent	382.2	388.9	348.7	618.1	706.2
Comprehensive Income — Non-controlling Interests	-7.9	5.1	22.7	28.0	10.9
Per Share — as-filed variants
Basic EPS — Continuing Operations	28.10	28.82	25.85	45.33	51.46
Diluted EPS — Continuing Operations	28.07	28.79	25.81	45.26	51.39
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,332.8	1,629.1	2,179.7	2,333.8	2,456.1
Gross Margin %	79.09	81.08	75.33	74.58	73.76
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	404.6	431.2	488.8	655.7	695.7
− Exceptional Items (reconciliation)	0.0	0.0	0.0	-17.2	-53.1
Net Income Adj (tax-effected)	374.2	397.1	374.7	664.8	771.5
EPS Adj	28.10	28.82	25.85	46.54	55.27
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00
Filed Debt Equity	—	—	0.76	0.61	0.59
Filed Dscr	—	—	2.24	2.91	3.12
Filed Iscr	—	—	3.11	4.40	5.15
Paid Up Equity Capital	13.6	13.6	13.6	13.9	13.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.